Biomedical Intelligence Lab

Identifying and developing medicines that address meaningful patient unmet needs, from R&D to commercial stages, requires consistent review and diligence to appropriately utilize resources. L.E.K. Consulting’s Biomedical Intelligence Lab (BIL) is a focused group within the broader Life Sciences Biopharma and Data & Analytics teams that leverages a data-driven lens to develop nuanced answers that can help life sciences organizations evaluate drug, pipeline and market opportunities — creating strategies that best align with their goals.

By combining public and proprietary data sources with sophisticated modeling, our BIL reduces the uncertainty life sciences companies face when making critical organizational decisions. The BIL supports biomedical science via artificial intelligence and other advanced analytics to drive value within the healthcare industry.

From R&D discovery to pipeline prioritization to clinical trial design and commercial opportunity assessment, our team helps clients translate data into insight — and insight into action.

Biotech capital allocation

The BIL develops more sensitive and tunable forecasts through combinatorial scenario modeling, simulation-based valuation and risk adjustment planning. These methods support biotech forecast planning and biotech financial modeling.

In today’s dynamic commercial environment, biopharma companies must move beyond static models and embrace forecasting approaches that reflect constantly evolving market complexity. The BIL supports organizations by using advanced simulation tools that strengthen both short- and long-term strategic planning.

Our revenue forecasting and valuation capabilities help clients: 

• Anticipate market trends by identifying evolving clinical and commercial inflection points by utilizing dynamic modeling tactics
• Optimize financial strategy by informing capital allocation through robust, risk-weighted valuation analysis
• Mitigate investment risk by evaluating key scenarios and stress-test investment decisions to support organizational risk management 

This approach enables clients to build confidence in resource planning and investment prioritization — even in uncertain markets. 

Platform and investment prioritization

Our BIL also aligns early scientific innovation with commercial potential through biomedical innovation, data-driven target analysis and modality evaluation. We focus on identifying and evaluating recent biomedical discovery and R&D innovation that can be leveraged to help clients achieve their clinical and commercial goals.

We prioritize staying ahead in drug development requires identifying scientific traction early — and knowing where it aligns with business objectives. The BIL applies bioinformatics, publication analytics and therapeutic modeling to uncover promising R&D pathways.

Our tools enable clients to: 

• Identify and prioritize new targets and indications by quantifying early-stage activity and unmet need using curated innovation datasets
• Evaluate modalities and platform technologies through comparing emerging mechanisms and technology options for strategic fit
• Overlay R&D and commercial priorities to ensure pipeline opportunities are matched to internal strengths and long-term goals

By bringing structure to early-stage decision-making, our BIL helps clients focus resources where they can drive the most value. 

Strategic trial design and commercial opportunity 

Our team enhances clinical trial design and market opportunity assessment through real-world insights into patient behavior and disease complexity. This includes identifying and evaluating patient-specific clinical trial design and segmentation strategies by leveraging real-world data analytics.

We know that understanding the patient journey is critical to successful development and launch planning. The BIL integrates claims data, treatment patterns and progression dynamics to help clients design trials that are grounded in real-world complexity.

With our data-driven trial and market opportunity frameworks, clients can: 

• Discover patient behaviors and gain insights into adherence, persistence and therapy transitions
• Characterize disease progression to understand how comorbidities and treatment patterns shape clinical outcomes
• Improve patient outcomes by identifying opportunities for better care delivery and patient support 

These insights lead to robust, representative trial designs and highly effective go-to-market strategies. 

Commercial and medical launch planning

The BIL also builds a targeted field strategy by mapping real-world provider behavior, call points and stakeholder influence.

A successful launch depends on understanding not just whom to engage, but how and where to engage them. The BIL leverages claims data and healthcare provider (HCP) analytics to help organizations design focused field strategies that align with actual treatment dynamics.

Our launch planning capabilities allow clients to: 

• Develop effective field force networks by identifying prescribing patterns, HCP demographics and high-impact influencers
• Enhance go-to-market strategy that can inform deployment plans with real-world treatment insights
• Empower provider engagement with more customized education and awareness efforts where they are most needed 

Demonstrated achievements:

• We helped a biopharma giant achieve 90%+ accuracy in COVID-19 demand forecasting. Our model boosted the organization’s agility and long-term pandemic planning.
• Our team partnered with a biopharma innovator to chart a bold roadmap for PROTACs, revealing high-impact targets and growth paths. The new strategy accelerated R&D and next-generation protein degradation therapies. 

By leveraging our proprietary workflows and processes, clients can confidently develop data-backed drug programs and commercial strategies that are grounded in the realities of the market. In an industry where precision matters and timing is everything, the ability to see around corners is a true competitive advantage. Our BIL isn’t just about better data — it’s about unlocking better decisions when they matter most.